ing
reduction of inflammatory lesion counts from baseline (about 75% vs 50% for vehicle in both studies).
Ivermectin was also well-tolerated and safe over the 12 week duration. The most frequent adverse reactions were skin disorders,
with a lower incidence for IVM 1% than vehicle. In addition, a higher proportion of patients were observed to have no skin dryness and itching after treatment with IVM 1%, suggesting improvement of rosacea symptoms. This better
tolerability profile and implied anti-inflammatory effect is consistent with the known properties of the avermectin class of drugs.8 Furthermore, patient-reported outcomes were consistent with these efficacy and safety results, with significantly more subjects treated with IVM 1% evaluating their rosacea improvement to be “good†or “excellent.†These findings are congruent with a greater proportion of IVM 1% subjects reporting improvement in general cutaneous- and also rosacea-specific quality of life measures.